| Fiorina, Paolo |
| Not yet recruiting | 3 | 170 | Europe | Sitagliptin | University of Milan | Covid19, Diabetes Mellitus, Type 2, CKD | 03/22 | 12/22 | | |
QWINT-4, NCT05462756 / 2021-005878-25: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections |
|
|
| Completed | 3 | 730 | Europe, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar | Eli Lilly and Company, Eli Lilly and Company | Type 2 Diabetes, Type 2 Diabetes Treated With Insulin | 02/24 | 02/24 | | |
| Active, not recruiting | 2 | 140 | Europe, US, RoW | Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo | Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a. | Recent Onset type1 Diabetes | 04/24 | 04/26 | | |
Sulfa-Zero, NCT04272359: Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus |
|
|
| Recruiting | N/A | 138 | Europe | Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas, Shift to new generation therapeutic regimens | University of Milan | T2DM (Type 2 Diabetes Mellitus), Diet, Healthy, Renal Function Disorder, Albuminuria | 10/21 | 12/21 | | |
| Completed | N/A | 90 | Europe | Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection, Positioning of the device for glycemic monitoring | University of Milan, Luigi Sacco University Hospital | COVID19, BETA-CELL FUNCTION | 10/21 | 12/21 | | |
| Recruiting | N/A | 52 | Europe | Medtronic MiniMed 780G with SmartGuard activation, Medtronic MiniMed 780G without SmartGuard activation | University of Milan | Type 1 Diabetes | 01/23 | 02/24 | | |
| Recruiting | N/A | 60 | Europe | | University of Milan | Diabetes Mellitus | 09/23 | 12/23 | | |
| Not yet recruiting | N/A | 1400 | Europe | Dapagliflozin 10mg, Forxiga | University of Milan | Type 2 Diabetes | 12/22 | 12/22 | | |
| Not yet recruiting | N/A | 800 | Europe | SGLT2 inhibitor, Jardiance, Synjardy, Forxiga, Xigduo, Invokana, Vokanamet, Steglatro, Segluromet | University of Milan | Type2Diabetes | 12/22 | 03/23 | | |
